Hepatitis B Injection Approved for Treating Acute Exposure
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Hepatitis B Injection Approved for Treating Acute Exposure

NEW YORK -- April 23, 2009 -- Health Canada has approved the hepatitis B immune globulin (human) injection (HepaGam B) for treating acute exposure to hepatitis B virus (HBV).

Specifically, the approval is for post-exposure prophylaxis (PEP) for acute exposure to blood containing hepatitis B surface antigen (HBsAg), perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons, and household exposure to persons with acute hepatitis B infection.

The most common expected adverse drug reactions for intravenous immune
globulins are chills, fever, headaches, vomiting, allergic reactions, nausea, arthralgia, and moderate low back pain.

SOURCE: Cangene

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities